A Randomized, Double Blinded, Parallel Study to Evaluate the Pharmacokinetics of Zanamivir After Single and Repeated Dose (300 mg and 600 mg) Infusion Administration in Healthy Chinese Adults
Phase of Trial: Phase I
Latest Information Update: 15 May 2017
At a glance
- Drugs Zanamivir (Primary)
- Indications Influenza virus infections
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 07 Jul 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 12 Jun 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 11 May 2015 Status changed from not yet recruiting to recruiting as per ClinicalTrials.gov record.